Heartflow opened lower at $59.00, compared with its previous close of $60.53. In the last trading session, the stock traded between $56.93 and $59.55. It showed a downward intraday trend.
return calculator
Time Period
An investment of $100 made 2 years ago in Heartflow is now worth
$ 200.00
giving a profit of
$ 100.00 (100.00%)
invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 9 Analysts
Buy
88.89%
Hold
11.11%
Sell
0%
Markets Today
Today's Change
$-3.03 (-5.01%)
Day High
$59.55
Day Low
$56.93
Day Open
$59.00
Prev Close
$60.53
Volume
11,22,803
1W Return
3.84%
1M Return
15.38%
3M Return
129.80%
6M Return
94.71%
1Y Return
53.25%
Fundamentals
Market Cap ($ Mn)
5,000
PE Ratio
-
PB Ratio
14.81
PEG Ratio
-
ROE
-
ROCE
-53.82%
EPS (TTM)
-
Investment Returns
1 Week
3.84%
1 Month
15.38%
3 Months
129.80%
6 Months
94.71%
9 Months
86.56%
Financials
Quarterly
All values in $ Mn
37.2
Mar 25
43.4
Jun 25
46.3
Sep 25
49.1
Dec 25
52.6
Mar 26
64.1
Jun 26
Updates
20Oct
Heartflow to report Q3 2026 financial results on November 12
Heartflow Inc. releases Q3 2026 financial results on November 12, 2026. Conference call scheduled for 4:30 pm ET on November 12, 2026. Technology adopted by more than 1,800 institutions globally. Platform validated through over 200 studies involving 365,000 patients.
10 days ago
28Aug
Heartflow FUSION trial confirms 44% drop in unnecessary invasive heart procedures
Heartflow FFRCT Analysis reduced unnecessary invasive coronary angiography by 44% in FUSION trial. One-year results show overall ICA rate fell to 43% vs 61% for standard care. Revascularization rates remained identical at 20% for both groups. Trial enrolled 528 patients with stable chest pain across 12 Dutch hospitals.
2mo ago
28Aug
Heartflow to present at Wells Fargo healthcare conference in Boston
Heartflow management to speak at Wells Fargo conference on Sept 9, 2026. Platform adopted by over 1,800 global institutions. Technology backed by more than 625 peer-reviewed publications. CTA image acceptance rates exceed 97%. Database contains over 200 million annotated CTA images.
HeartFlow Inc. (NASDAQ: HTFL) reported Q2 2026 revenue of $64.1 million, up 48% YoY, driven by strong U.S. adoption of its FFRct and Plaque diagnostic platforms. The company posted an adjusted loss of 7 cents per share, beating estimates of a 13-cent loss, and raised full-year 2026 revenue guidance to $246-250 million. Shares surged 35.86% to a 52-week high of $42.13 on the news.
2mo ago
14Aug
Piper Sandler raises HeartFlow price target to $45, keeps Overweight
Piper Sandler maintained its Overweight stance on HeartFlow while increasing the price target to $45 from $38. Analyst Matt OBrien led the review, signaling confidence in the stock's trajectory.
2mo ago
14Aug
JP Morgan raises HeartFlow price target to $45, maintains Overweight
JP Morgan analyst Robbie Marcus maintains an Overweight rating on HeartFlow (NASDAQ: HTFL). The bank raised its price target from $35 to $45, signaling continued confidence in the stock's potential.
